Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Eurocine Vaccines AB (publ) (8X4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0908-0.0040 (-4.22%)
At close: 08:05AM CET
Advertisement

Eurocine Vaccines AB (publ)

Nanna Svartz vAeg 4
Solna 171 65
Sweden
46 7 06 34 01 71
https://www.eurocine-vaccines.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. Hans Arwidsson Ph.D.CEO, Pres & DirectorN/AN/A1958
Dr. Anna-Karin MaltaisChief Scientific Officer, VP of R&D and Member of Scientific Advisory BoardN/AN/AN/A
Dr. Marie OlliverDirector of Clinical Devel.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Eurocine Vaccines AB (publ) engages in the development of vaccines in Sweden. It has a research and collaboration agreement with Spixia Biotechnology AB to develop, manufacture, and commercialize chlamydia vaccine candidates. The company was incorporated in 1999 and is based in Solna, Sweden.

Corporate Governance

Eurocine Vaccines AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement